Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase.

Conventional treatments to combat the tuberculosis (TB) epidemic are falling short, thus encouraging the search for novel antitubercular drugs acting on unexplored molecular targets. Several whole-cell phenotypic screenings have delivered bioactive compounds with potent antitubercular activity. However, their cellular target and mechanism of action remain largely unknown. Further evaluation of these compounds may include their screening in search for known antitubercular drug targets hits. Here, a collection of nearly 1400 mycobactericidal compounds was screened against Mycobacterium tuberculosis NaMN adenylyltransferase ( MtNadD), a key enzyme in the biogenesis of NAD cofactor that was recently validated as a new drug target for dormant and active tuberculosis. We found three chemotypes that efficiently inhibit MtNadD in the low micromolar range in vitro. SAR and cheminformatics studies of commercially available analogues point to a series of benzimidazolium derivatives, here named N2, with bactericidal activity on different mycobacteria, including M. abscessus, multidrug-resistant M. tuberculosis, and dormant M. smegmatis. The on-target activity was supported by the increased resistance of an M. smegmatis strain overexpressing the target and by a rapid decline in NAD(H) levels. A cocrystal structure of MtNadD with N2-8 inhibitor reveals that the binding of the inhibitor induced the formation of a new quaternary structure, a dimer-of-dimers where two copies of the inhibitor occupy symmetrical positions in the dimer interface, thus paving the way for the development of a new generation of selective MtNadD bioactive inhibitors. All these results strongly suggest that pharmacological inhibition of MtNadD is an effective strategy to combat dormant and resistant Mtb strains.

Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in southern California.

Southern California imports nearly all of its potable water from two sources: the Colorado River and the California State Water Project (Sacramento-San Joaquin River Basin). Sewage treatment plant effluent (STPE) heavily impacts both of these sources. A survey of raw and treated drinking water from four water filtration plants in San Diego County showed the occurrence of several polar organic "pharmaceuticals and personal care products" (PPCP). These included phthalate esters, sunscreens, clofibrate, clofribric acid, ibuprofen, triclosan, and DEET. Several of these were also found in the finished water, such as di(ethylhexyl) phthalate, benzophenone, ibuprofen, and triclosan. Occurrence and concentrations of these compounds were highly seasonally dependent, and reached maximums when the flow of the San Joaquin River was low and the quantity of imported water was high. The maximum concentrations of the PPCPs measured in the raw water were correlated with low flow conditions in the Sacramento-San Joaquin Delta that feeds the State Water Project. The PPCP concentrations in raw imported water in the summer months approached that of reclaimed nonpotable wastewater.